DXY
A healthcare connector and digital professional service provider
DXY, founded in November, 2005 and headquartered in Hangzhou, is a medical service platform. Established by Li Tiantian and Zhou Shuzhong, the company has received financings from Tencent Investment, Shunwei Capital, DCM China and so on. Rivals that have direct and indirect competition with DXY globally include 100 XHS, Chunyuyisheng, Practo, etc.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Backed up by Rich Dad – What’s Next for Ping An Good Doctor?
Having a rich dad can help with capital and connections when a company is at the ‘infant’ stage. But being independent comes sooner or later. When shall that be for Ping An Good Doctor? Or will it not come at all?
Aug 27, 2020 01:02 PM
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Updated 6 hours ago
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
First class recall of Draeger, a ventilator giant
Chuanfa longmang: it plans to set up a joint venture with China Innovation airlines to invest in the lithium resource deep processing project